<DOC>
	<DOCNO>NCT01172392</DOCNO>
	<brief_summary>The purpose study assess loss HbsAg 48-week pegylated interferon alpha 2a patient chronic hepatitis B ( HBeAg negativation )</brief_summary>
	<brief_title>A Randomized Study Assess Loss HbsAg After 48-week Treatment Period With Pegylated Interferon Alpha 2a Patients With Chronic Hepatitis B</brief_title>
	<detailed_description>The purpose study provide therapeutical alternative use extend undeterminated duration treatment prolong nucleoside ( ) /nucleotide ( ) analog ( ) . The duration administration consensual , case follow virological relapse , , prolong use could lead occurrence viral resistance mutation . It therefore expect treatment pegylated interferon 48 week patient undetectable HBV DNA analog ( ) may increase promotes loss HbsAg promote HbsAg seroconversion . In absence cirrhosis , loss HbsAg 6 month would allow end treatment</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Positive Hbs Ag Negative HbeAg Plasma HBV DNA undetectable preinclusion ever since 12 month ALT le equal 5 time upper limit normal Non cirrhotic Not Decompensated Cirrhosis ( Child Pugh &lt; 7 ) Undetectable hepatocellular carcinoma liver scan / alphafetoprotein rate &lt; 50 ng / ml Unchanged nucleoside ( ) / nucleotide ( ) treatment least three month ( include telbivudine ) Negative pregnancy test childbearing woman Signed informed consent Use contraception childbearing woman Polymorphonuclear neutrophils &lt; 1500/mm3 Platelets &lt; 70.000/mm3 Coinfections HIV , HCV / HDV Prolonged excessive consumption alcohol Active intravenous drug addiction Immunomodulators Treatment ( eg interferon ) , ever since one year Immunosuppressive treatment terminate ever since one year Telbivudine treatment Long course steroid treatment ( 4 week ) oral way History severe epilepsy current use anticonvulsant Severe heart disease ( eg heart failure stage III IV NYHA class , myocardial infarction le 6 month , ventricular arrhythmia require treatment , unstable angina significant cardiovascular disease ) Chronic liver disease HBVrelated ( hemochromatosis , autoimmune hepatitis , metabolic liver disease , include Wilson 's disease deficiency alpha1antitrypsin deficiency , alcoholic liver disease , exposure toxin ) Presence suspicion cancer history cancer ( except basal cell carcinoma situ carcinoma ) within 5 year precede randomization Thyroid uncontrolled disease , abnormal TSH , elevate thyroid antibody clinical manifestation thyroid dysfunction History autoimmune disease ( inflammatory digestive , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis ... . ) Or presence autoantibody significant rate Renal impairment ( creatinine clearance &lt; 50 ml / min use Cockroft formula ) , renal transplantation , hemodialysis Hypersensitivity active substance , interferon alpha component History depression psychiatric disorder uncontrolled depression uncontrolled psychiatric disorder Pregnancy breastfeeding , wish pregnancy study period . Patients legal protection unable express consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>